Investigating the Synergistic Effects of Pembrolizumab and Chemotherapy in Gastric and Gastroesophageal Junction Cancer
The observed PFS with ICT was comparable to the predicted PFS based on the data for each monotherapy. Our findings do not provide direct evidence of synergistic effects, but they suggest that combining ICI and chemotherapy does not compromise efficacy. These results may support the continued clinical use of ICT in patients with advanced GC/GEJC.
Authors
- Kenro Hirata (ORCID: https://orcid.org/0000-0003-4536-7781)
- Yuko Kitagawa (ORCID: https://orcid.org/0000-0001-6469-2155)
- Yasunori Sato (ORCID: https://orcid.org/0000-0002-7189-5126)
- Masashi Takeuchi (ORCID: https://orcid.org/0000-0003-3797-432X)
- Kengo Nagashima (ORCID: https://orcid.org/0000-0003-4529-9045)
- Kai Tsugaru (ORCID: https://orcid.org/0000-0001-7763-7999)
- Jun Okui (ORCID: https://orcid.org/0000-0002-5226-1347)
- Satoru Matsuda (ORCID: https://orcid.org/0000-0001-8441-2755)
- Motoo Nomura (ORCID: https://orcid.org/0000-0002-5967-0610)
- Ken Kato (ORCID: https://orcid.org/0000-0002-1733-5072)
- Hirofumi Kawakubo (ORCID: https://orcid.org/0000-0002-6246-7023)
- Takahiro Tsushima (ORCID: https://orcid.org/0000-0003-3551-7504)
- Shun Yamamoto
- Hiroya Takeuchi
Institutions
- Keio University (JP)
- Hamamatsu University School of Medicine (JP)
- Shizuoka Cancer Center (JP)
- Keio University Hospital (JP)
- National Cancer Center Hospital East (JP)
- Kyoto University Hospital (JP)
Publication Details
- Journal
- Journal of the Korean Gastric Cancer Association
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5230/jgc.2025.25.e33
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Keio University